← Back to Screener
Cogent Biosciences, Inc. Common Stock (COGT)
Price$31.02
Value ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-30.80%
Price vs S&P 500 (4W)-10.70%
VGM Score35.28
Market Capitalization$5.30B
All Metrics
Book Value / Share (Quarterly)$3.56
P/TBV (Annual)2.25x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.68
Price vs S&P 500 (YTD)-20.83%
Net Profit Margin (TTM)-264.08%
EPS (TTM)$-2.51
10-Day Avg Trading Volume2.68M
EPS Excl Extra (TTM)$-2.51
EPS (Annual)$-2.46
ROI (Annual)-99.89%
Net Profit Margin (5Y Avg)-407.35%
Cash / Share (Quarterly)$5.07
ROA (Last FY)-78.07%
EBITD / Share (TTM)$-2.60
ROE (5Y Avg)-59.00%
Operating Margin (TTM)-295.77%
Cash Flow / Share (Annual)$-1.65
P/B Ratio8.72x
P/B Ratio (Quarterly)10.28x
Net Income / Employee (Annual)$-992,200
EV / Revenue (TTM)228.08x
ROA (TTM)-55.77%
EPS Incl Extra (Annual)$-2.46
Current Ratio (Annual)14.23x
Quick Ratio (Quarterly)14.94x
3-Month Avg Trading Volume1.98M
52-Week Price Return417.86%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.52
P/S Ratio (Annual)673.48x
Asset Turnover (Annual)0.03x
52-Week High$43.73
Operating Margin (5Y Avg)-434.04%
EPS Excl Extra (Annual)$-2.46
CapEx CAGR (5Y)80.39%
Tangible BV CAGR (5Y)55.30%
26-Week Price Return-22.87%
Quick Ratio (Annual)14.08x
13-Week Price Return-17.19%
Total Debt / Equity (Annual)0.35x
Current Ratio (Quarterly)15.14x
Enterprise Value$5.28B
Asset Turnover (TTM)0.36x
Book Value / Share Growth (5Y)-11.46%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-950.57%
Cash / Share (Annual)$5.60
3-Month Return Std Dev44.96%
Net Income / Employee (TTM)$-1,373,300
ROE (Last FY)-99.89%
EPS Basic Excl Extra (Annual)$-2.46
Receivables Turnover (TTM)7.87x
Total Debt / Equity (Quarterly)0.37x
EPS Incl Extra (TTM)$-2.51
Receivables Turnover (Annual)7.87x
ROI (TTM)-63.39%
P/S Ratio (TTM)228.86x
Pretax Margin (5Y Avg)-407.35%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.66
Price vs S&P 500 (52W)393.50%
Year-to-Date Return-12.67%
5-Day Price Return-10.89%
EPS Normalized (Annual)$-2.46
ROA (5Y Avg)-49.41%
Net Profit Margin (Annual)-950.57%
Month-to-Date Return-11.27%
Cash Flow / Share (TTM)$-2.32
EBITD / Share (Annual)$-2.63
Operating Margin (Annual)-1044.47%
LT Debt / Equity (Annual)0.35x
ROI (5Y Avg)-59.00%
LT Debt / Equity (Quarterly)0.37x
EPS Basic Excl Extra (TTM)$-2.51
P/TBV (Quarterly)1.90x
P/B Ratio (Annual)8.49x
Pretax Margin (TTM)-264.08%
Book Value / Share (Annual)$3.95
Price vs S&P 500 (13W)-25.45%
Beta0.44x
P/FCF (Annual)336.96x
Revenue / Share (TTM)$0.00
ROE (TTM)-83.29%
52-Week Low$5.49
vGradeF
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.60est. -0.55
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.26
4.26
4.26
4.26
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
COGTCogent Biosciences, Inc. Common Stock | F | — | C | $31.02 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Cogent Biosciences develops precision therapies for genetically defined diseases. Its lead program, CGT9486, is a selective tyrosine kinase inhibitor targeting KIT mutations—specifically D816V mutations that drive Systemic Mastocytosis and exon 17 mutations found in advanced gastrointestinal stromal tumors (GIST). The company addresses significant unmet medical needs in these serious hematologic and oncologic conditions.